| Statins |
0 |
1 |
| Lipids Management |
0 |
0.85 |
| COVID-19 |
0 |
0.95 |
| Hypertension |
0 |
0.42 |
| Cardiovascular Risk Management |
0 |
0.9 |
| Antihypertensive Agents |
0 |
0.19 |
| California |
0 |
0.19 |
| Cardiovascular disease |
0 |
0.8 |
| Revenue and Practice Management |
0 |
0.1 |
| Hospital |
0 |
0.09 |
| Intensive Care Unit |
0 |
0.09 |
| Match |
0 |
0.07 |
| Ohio |
0 |
0.07 |
| Health Care Reform |
0 |
0.05 |
| Heart |
0 |
0.05 |
| Insurance |
0 |
0.05 |
| Angiotensin II Receptor Blockade |
0 |
0.03 |
| ACE Inhibitor |
0 |
0.02 |
| Acute Respiratory Distress Syndrome |
0 |
0.02 |
| Cerebrovascular Accident |
0 |
0.02 |
| Clinical Research |
0 |
0.02 |
| Outpatient Clinic |
0 |
0.02 |
| Pandemic |
0 |
0.02 |
| Receptors |
0 |
0.02 |
| Severe Acute Respiratory Syndrome (SARS) |
0 |
0.02 |
| Stress |
0 |
0.02 |